Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours. 

An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited

Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST

Survival benefits of the radioligand therapy needs to be confirmed in further studies

A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials

A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors 

Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.

Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings

In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy

Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials